Text Size

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

This study has been terminated.
(Portfolio consolidation.)
Sponsor:
Information provided by (Responsible Party):
Emergent BioSolutions
ClinicalTrials.gov Identifier:
NCT00893516
First received: May 5, 2009
Last updated: February 25, 2013
Last verified: February 2013
History of Changes
  Purpose

Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma.


Condition Intervention Phase
T-cell Lymphoma
 Biological: CHOP + CD4
Drug: CHOP
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.

Resource links provided by NLM:

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Further study details as provided by Emergent BioSolutions:

Enrollment: 5
Study Start Date: May 2007
Study Completion Date: December 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
CHOP chemo therapy + CD4 therapy
 Biological: CHOP + CD4
Active Comparator: 2
CHOP chemotherapy
 Drug: CHOP

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • study is closed to enrollment

Exclusion Criteria:

  • study is closed to enrollment
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Emergent BioSolutions
ClinicalTrials.gov Identifier: NCT00893516     History of Changes
Other Study ID Numbers: GEN112
Study First Received: May 5, 2009
Last Updated: February 25, 2013
Health Authority: Netherlands: Medicines Evaluation Board (MEB)
Switzerland: Swissmedic
Germany: Federal Institute for Drugs and Medical Devices
Italy: Ministry of Health

Keywords provided by Emergent BioSolutions:
non cutaneous peripheral t-cell lymphoma with nodal involvement

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin

ClinicalTrials.gov processed this record on May 22, 2013